Company Overview of Medinox, Inc.
Medinox, Inc. operates as a pharmaceutical company. It develops small molecule drugs to treat various unmet medical needs, including sepsis, arthritis and inflammation, diabetes, and sickle cell anemia. The company’s research and clinical development programs include nitric oxide neutralizers, such as NOX-100, an injectable compound for septic shock; and oral compounds for type-2 diabetes. It also develops Prodrug programs, such as non steroidal anti-inflammatory drugs for treating inflammation and pain; MX-1094, a naproxen; and MX-1520, a sickle cell anemia therapeutic. The company was founded in 1995 and is based in Carlsbad, California.
6120 Paseo Del Norte
Carlsbad, CA 92009
Founded in 1995
Key Executives for Medinox, Inc.
Similar Private Companies By Industry
|Bioplus Pharmaceuticals Inc.||United States|
|Kremers Urban Development Company, Inc.||United States|
|Bristol-Myers Squibb Manufacturing Company||United States|
|Astrazeneca Neuroscience Innovative Medicines||United States|
|Sport Specific Performance||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Medinox, Inc., please visit www.medinox.com. Company data is provided by Capital IQ. Please use this form to report any data issues.